HC Wainwright Initiates Coverage on NeuroSense Therapeutics (NASDAQ:NRSN)

HC Wainwright assumed coverage on shares of NeuroSense Therapeutics (NASDAQ:NRSN) in a research report issued to clients and investors on Thursday, Benzinga reports. The brokerage set a “buy” rating on the stock.

Separately, Weiss Ratings cut NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $8.50.

NeuroSense Therapeutics Stock Down 2.2%

NASDAQ:NRSN opened at $0.41 on Thursday. NeuroSense Therapeutics has a 52 week low of $0.25 and a 52 week high of $1.98. The stock has a market cap of $15.51 million, a price-to-earnings ratio of -0.76 and a beta of 1.60. The company’s 50 day moving average price is $0.56 and its 200-day moving average price is $0.72.

Insider Buying and Selling at NeuroSense Therapeutics

In other news, CEO Alon Ben-Noon acquired 250,000 shares of NeuroSense Therapeutics stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the transaction, the chief executive officer owned 4,534,233 shares in the company, valued at $3,627,386.40. The trade was a 5.84% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Or Eisenberg purchased 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at approximately $1,203,240. This trade represents a 19.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 27.40% of the company’s stock.

Institutional Trading of NeuroSense Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Two Sigma Investments LP bought a new position in shares of NeuroSense Therapeutics in the third quarter worth about $26,000. Jane Street Group LLC purchased a new stake in NeuroSense Therapeutics in the 2nd quarter worth $54,000. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics during the second quarter valued at about $56,160. Finally, Squarepoint Ops LLC lifted its position in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares in the last quarter. 1.04% of the stock is owned by hedge funds and other institutional investors.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.